Apr 23 |
Day One wins FDA nod for brain cancer therapy, Ojemda
|
Apr 15 |
Viracta slides on lower response rate in trial for lymphoma treatment cohort
|
Apr 15 |
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
|
Mar 7 |
Viracta Therapeutics GAAP EPS of -$0.35 misses by $0.04
|
Mar 7 |
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
Feb 29 |
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
|
Feb 6 |
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
|
Jan 5 |
CACI International To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Friday
|
Jan 4 |
Viracta Therapeutics Provides Clinical Update and Outlook for 2024
|
Dec 12 |
Viracta gets orphan drug status for Nana-val for EBV tumors
|